Why did West Pharma sell the SmartDose technology?

The sale is part of West Pharma's strategy to refocus on its core drug delivery and packaging solutions, moving away from wearable injectors.

Was the deal value disclosed?

The financial terms of the deal were not disclosed.

How did the deal affect ABBV and WST stocks?

Both stocks remained relatively stable; analysts view the deal as positive for both companies.

AbbVie Acquires SmartDose Technology from West Pharma

West Pharmaceutical Services (WST) sold the rights and facilities of its SmartDose 3.5 mL On Body Delivery System to AbbVie (ABBV), enabling AbbVie to expand its wearable injector portfolio while West refocuses on its core offerings.

July 10, 2026

2 min read

Source: Simply Wall St.

West Pharmaceutical Services (NYSE:WST) announced the sale of rights and facilities related to its SmartDose 3.5 mL On Body Delivery System to AbbVie (NYSE:ABBV).

Deal Details

Seller: West Pharmaceutical Services (WST)
Buyer: AbbVie (ABBV)
Asset: SmartDose 3.5 mL On Body Delivery System (large volume wearable injector)
Includes: Intellectual property rights and associated facilities
Value: Not disclosed

Rationale

West Pharma is refocusing its portfolio on drug delivery and pharmaceutical packaging solutions outside the wearable injector space. For AbbVie, the acquisition strengthens its drug delivery capabilities, particularly for chronic disease treatments requiring large-volume injections.

Regulatory Hurdles

The deal is subject to customary regulatory approvals, but no major obstacles are anticipated given the specialized nature of the assets.

Stock Impact

Shares of ABBV and WST remained relatively stable following the announcement. The transaction is viewed as strategically positive for both companies: AbbVie expands its technology platform, while West sharpens its strategic focus.

Frequently Asked Questions

SmartDose is a 3.5 mL wearable injector system for on-body drug delivery, suitable for large-volume biologic drugs.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.